antidiabetic effects glucokinase regulatory protein small-molecule disruptors
glucose homeostasis vital complex process disruption can cause hyperglycaemia type ii diabetes mellitus glucokinase gk key enzyme regulates glucose homeostasis converts glucose glucose--phosphate pancreatic beta-cells liver hepatocytes specific hypothalamic neurons gut enterocytes hepatocytes gk regulates glucose uptake glycogen synthesis suppresses glucose production subject endogenous inhibitor gk regulatory protein gkrp- fasting gkrp binds inactivates sequesters gk nucleus removes gk gluconeogenic process prevents futile cycle glucose phosphorylation compounds directly hyperactivate gk gk activators lower blood glucose levels evaluated clinically potential therapeutics treatment type ii diabetes mellitus however initial reports indicate increased risk hypoglycaemia associated gk activators mitigate risk hypoglycaemia sought increase gk activity blocking gkrp describe identification two potent small-molecule gk-gkrp disruptors amg amg- normalized blood glucose levels several rodent models diabetes compounds potently reversed inhibitory effect gkrp gk activity promoted gk translocation vitro isolated hepatocytes vivo liver co-crystal structure full-length human gkrp complex amg revealed previously unknown binding pocket gkrp distinct phosphofructose-binding site furthermore amg amg gk activators blood glucose lowering restricted diabetic normoglycaemic animals findings exploit new cellular mechanism lowering blood glucose levels reduced potential hypoglycaemic risk patients type ii diabetes mellitus
